长春高新：关于子公司替勃龙片在境内获批上市的公告

Core Viewpoint - Changchun Gaoxin announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing of Teborone tablets in China [2] Company Summary - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical, has successfully obtained a drug registration certificate for Teborone tablets [2]